James R. Berenson, MD, Inc.

Tag Archives: bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory

Replacement of Bortezomib with Carfilzomib for Multiple Myeloma Patients Progressing from Bortezomib Combination Therapy

March 5, 2017

J R Berenson^1,2,3, J D Hilger², O Yellin², R Dichmann… Article

Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:

Monoclonal gammopathy of undetermined significance (MGUS)
Asymptomatic (smoldering/indolent) myeloma
solitary plasmacytoma of the bone
Extramedullary plasmacytoma
Light chain myeloma
Non-secretory myeloma
Osteosclerotic myeloma (POEMS syndrome)
Waldenstrom macroglobulinemia
Light chain amyloidosis
Plasma cell leukemia

Tag Archives: bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory

Replacement of Bortezomib with Carfilzomib for Multiple Myeloma Patients Progressing from Bortezomib Combination Therapy

James R. Berenson, MD

Links

Subscribe

Contact Us